

# Quanterix™

## Quanterix Corporation to Release First Quarter 2022 Financial Results on May 10, 2022

May 3, 2022

BILLERICA, Mass.--(BUSINESS WIRE)--May 3, 2022-- [Quanterix Corporation](#) (NASDAQ: QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, today announced that it will release its financial results for first quarter 2022 before the start of trading on May 10, 2022. Company management will host a conference call at 8:30 a.m. EST to discuss Quanterix' financial results and provide a business update. The call will be hosted by Masoud Toloue, the Company's President and Chief Executive Officer, and Michael Doyle, the Company's Chief Financial Officer.

Individuals interested in listening to the conference call may do so by dialing (833) 686-9351 for domestic callers, or (612) 979-9890 for international callers. Please reference the following conference ID: 4589034. A live webcast will also be available at: <https://edge.media-server.com/mmc/p/vt3rqv39>.

The webcast will be available on the Company's website, <http://www.quanterix.com>, for one year following completion of the call.

To access the live webcast of Quanterix' presentations, please visit the [News & Events](#) page within the Investors section of the Quanterix website at [www.quanterix.com](http://www.quanterix.com). Replays of the webcasts will be available on the Quanterix website for 90 days following the conference.

### About Quanterix

Quanterix is a company that's digitizing biomarker analysis with the goal of advancing the science of precision health. The company's digital health solution, Simoa, has the potential to change the way in which healthcare is provided today by giving researchers the ability to closely examine the continuum from health to disease. Quanterix' technology is designed to enable much earlier disease detection, better prognoses and enhanced treatment methods to improve the quality of life and longevity of the population for generations to come. The technology is currently being used for research applications in several therapeutic areas, including oncology, neurology, cardiology, inflammation and infectious disease. The company was established in 2007 and is located in Billerica, Massachusetts. For additional information, please visit <https://www.quanterix.com>.

### Forward-Looking Statements

*This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "plan," "anticipate," "estimate," "intend" and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Forward-looking statements in this news release are based on Quanterix' expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Factors that may cause Quanterix' actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in Quanterix' filings with the U.S. Securities and Exchange Commission, including the "Risk Factors" sections contained therein. Except as required by law, Quanterix assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.*

View source version on [businesswire.com](https://www.businesswire.com): <https://www.businesswire.com/news/home/20220503005215/en/>

### Media Contact:

PAN Communications  
Lauren Force  
(610) 574-0565  
[pan.quanterix@pancomm.com](mailto:pan.quanterix@pancomm.com)

### Investor Relations Contact:

Stephen Hrusovsky  
(774) 278-0496  
[shrusovsky@quanterix.com](mailto:shrusovsky@quanterix.com)

Source: Quanterix Corporation